Gary Shearman, Ph.D.

Chairman

Dr. Shearman is a seasoned pharmaceutical industry executive and biopharmaceutical venture capitalist. He has extensive global research and drug development leadership experience in multiple therapeutic areas and venture capital investing in a variety of private and public biotech, medtech and diagnostic companies. Dr. Shearman was responsible for creating and implementing global drug development and regulatory strategies resulting in over twenty regulatory submissions and product approvals on a worldwide basis in major markets such as the United States, the European Union and Japan. He reengineered global drug development operations achieving highly competitive drug development times and quality and he managed diverse research and drug development functions located in various countries.

Between 2001 and 2007, Dr. Shearman served as Chairman and Managing Director of HBM Advisors USA, LLC, a provider of advisory services for HBM Partners (Cayman) Ltd, the investment manager for all HBM investment vehicles including HBM BioVentures and HBM BioCapital, holding companies in the human medicine, biotechnology and medical technology industries.

From 1998 until 2000, Dr. Shearman was Deputy Head of Global Research and Drug Development and Senior Vice President of Global Drug Development at Rhone-Poulenc Rorer (now Sanofi/Aventis). He was responsible for ensuring the global implementation of the corporate product strategy and coordinated all R&D, marketing and manufacturing activities related to two blockbuster oncology drugs (Taxotere & CPT-11) and the low molecular weight heparin, Lovenox.

From 1994 until 1998, Dr. Shearman was Senior Vice President of Pharmaceutical Drug Development for Rhone-Poulenc Rorer. He oversaw all drug development and regulatory activities worldwide and directed departments with a consolidated annual budget of approximately $450 million.

Dr. Shearman was Director Regulatory International Affairs (1989-1992) and Associate Director Clinical Neurosciences (1987 - 1988) for Merck & Co. From 1983 until 1987, he worked for Sandoz (now Novartis) in drug discovery and as a project leader for central nervous system (CNS) products.

Dr. Shearman received a Ph.D. in pharmaceutical sciences and an MS in pharmacology and toxicology from the University of Rhode Island and a BA in psychology from the University of Massachusetts. Gary was a post-doctoral fellow at the Max-Planck Institute for Psychiatry in Munich, Germany (1980-1982). He was a member of the R & D advisory board for the Center Medicines Research Institute and Tufts Center for the Study of Drug Development.

Dr. Shearman has been a member of the Board of Directors of ChemoCentryx, Innodia, and Neuro-Hitech. He currently serves on the Board of Directors of Artisan Pharma.

Jean Deleage

Dr. Deleage is a managing general partner of Alta Partners, a spin-off from Burr, Egan, Deleage & Co. He has been an investor in biopharmaceutical and high technology companies since 1971. He founded Sofinova, a venture capital organization in Paris, France, and in 1976 became president of Sofinova, Inc., in the United States. He currently serves on the boards of Flamel Technologies, Aclara Biosciences and Telik, Inc., as well as many private companies.

Dr. Deleage received a master's degree in electrical engineering from the Ecole Superieure d'Electricite and a doctorate in economics from the Sorbonne. In 1993, he was awarded the Legion of Honor from the French government.

Jason Fisherman, M.D.

Dr. Fisherman joined Advent International in 1994 and has led or co-led Advent’s investments in over 20 companies. He is currently a board member of Achillion Pharmaceuticals Inc., Anadys Pharmaceuticals Inc., Cellzome AG, Crucell NV, Exelixis Inc., ILEX Oncology Inc., Neurogenetics Inc. and Oridion Systems Ltd. He has 10 years of venture capital experience and nine years of drug research and clinical development experience.

Prior to Advent, Dr. Fisherman was senior director of medical research at Enzon, where he managed clinical programs in oncology, genetic diseases and blood substitutes. Previously, at the National Cancer Institute, he was responsible for developing a portfolio of anticancer drugs, including Taxol. While a research fellow at Dana Farber Cancer Institute, he focused on the regulation of gene transcription and molecular oncology.

Dr. Fisherman received a bachelor’s degree in molecular biophysics and biochemistry from Yale, an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School of the University of Pennsylvania. He is board certified in internal medicine and medical oncology.

Standish M. Fleming

A 16-year veteran of early stage investing, Mr. Standish Fleming co-founded Forward Ventures as a venture capital investment firm. Throughout his career at Forward Ventures, Mr. Fleming has served as acting president of Triangle Pharmaceuticals, Actigen , GenQuest and CombiChem. He was a founding board member of Ciphergen Biosystems, Gryphon Sciences and Triangle Pharmaceuticals. Mr. Fleming is a former president of the Biotechnology Venture Investors' Group. Mr. Fleming now serves as a director of Acorda, Arizeke, Ambit, Nereus, Kemia, Converge and Sanarus.

He earned his bachelor's in arts from Amherst College and master's in business administration from the UCLA Graduate School of Management.

Erich Platzer, MD

Dr. Platzer is an investment advisor with HBM Partners, advisors to HBM BioVentures in Zurich, Switzerland. Previously he was head of oncology at Roche. He has over 10 years of operating experience in product development and marketing. Dr. Platzer also practiced as a physician and researcher for numerous years and was a member of the team that first purified G-CSF (Neupogen). He graduated from the Medical School of the University of Erlangen, where he also received his PhD. He is currently Vice Chairman of MTM Laboratories, and serves on the Board of Cylene, Locus, and ProBiodrug.

Jesper Zeuthen, D.Sc

Professor Zeuthen is the managing director of the management company BI Technology A/S within the BankInvest Group, seven different venture funds focusing on biotech drug development raised in the period 1998-2006 and with more than 30 portfolio companies in Europe and in the USA, the two companies acting as general partners of these venture funds and Kuros Holding ApS. He was previously Head of Research & Development at Novo Nordisk A/S and Head of Research at the Danish Cancer Society. Professor Zeuthen I Chairman of the Board of Borean Pharma ApS, Vice-Chairman of the Danish Biotechnology Research and Innovation Centre (BRIC) and substitute member of the Board of CMC Biopharmaceuticals A/S. He has previously been a member of the Board of Directors of Genmab A/S (Chairman), Roche Bio Denmark A/S (Chairman), Santaris Pharma A/S (Chairman), Zymenex Holding A/S (Chairman), Fibrogen Europe Oy and BioVision A/S. Professor Zeuthen is the author of more than 200 publications on immunology, cell biology and molecular biology and is an adjunct professor of biotechnology at the University of Copenhagen.

Kobi M. Sethna, President and Chief Executive Officer

Bio in Management Section.

Directors Emeritus

Frank V. AtLee

Mr. AtLee is retired chairman and CEO of Monsanto Company, a U.S.-based multinational corporation that provides integrated technology-based agricultural solutions for growers and downstream customers in agricultural markets. Previously, he was president and a board member of American Cyanamid Company, a research-based life sciences company involved with the discovery and development of medical and agricultural products, and chairman of Cyanamid International.

Mr. AtLee has served on the boards of trustees of Ramapo College of New Jersey and the Foundation of the University of Medicine and Dentistry of New Jersey. He is currently a director of Antigenics Inc., a publicly traded biotechnology company based in New York City. He has served as an officer in the U.S. Marine Corps. Mr. AtLee is a graduate of Lynchburg College in Lynchburg, Virginia, where he obtained a bachelor's of science degree in chemistry and biology.

Martin Rosenberg, Ph.D.

Dr. Martin Rosenberg is currently the Chief Scientific Officer of the Promega Corporation, Madison, WI. He joined Promega after retiring in 2001 as Senior Vice President of Anti-Infectives Drug Discovery and Development at GlaxoSmithKline. He spent 20 years in the SmithKline R&D Organization and served as Senior Vice President in R&D since 1993. Dr. Rosenberg serves on the Board of Directors for the Promega Corporation, Madison, WI; the Medical College of Wisconsin Research Foundation, Milwaukee, WI; Nereus Pharmaceuticals, Inc., San Diego, CA; Anacor Pharmaceuticals, Palo Alto, CA; and Scarab Genomics, Madison, WI. He also serves on a variety of academic and industry Scientific Advisory Boards and holds an adjunct Professorship at the University of Wisconsin, Department of Bacteriology, Madison, WI. Dr. Rosenberg is Editor-in-Chief of Current Opinions in Biotechnology, a Section Editor of the Journal of Bacteriology and a member of several other journal Editorial Boards.

Before joining SmithKline Pharmaceutical R&D he spent 10 years at the National Institutes of Health and was a Section Chief in the National Cancer Institute. He has served as a member of the Executive Council for the National Institute of Allergy & Infectious Disease as well as a member of the Science Advisory Board of the FDA. He has been awarded the Arthur S. Fleming Award, the Panlabs Award in Microbiology, and the Distinguished Alumni Award from Purdue University. Dr. Rosenberg received his Ph.D. from Purdue and his postdoctoral training at Yale Medical School. He has published more than 200 papers and is the named inventor on more than 50 issued patents.